Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan versus irbesartan dose-escalation study in focal segmental glomerulosclerosis
2014-002358-38Phase 2Completed
- Sponsor
- Travere Therapeutics
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sparsentan in focal segmental glomerulosclerosis (FSGS) (4 arms), sponsored by Travere Therapeutics. Primary endpoint: Change from baseline to Week 8 in natural log urine protein/creatinine ratio. Started Oct 2014; status: completed.
02
Drugs
sparsentan
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2014-002358-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002358-38.